{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:18:51Z","timestamp":1783423131446,"version":"3.54.6"},"reference-count":70,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br. J. Hosp. Med. (Lond)"],"abstract":"<jats:p>Recurrent urinary tract infection (rUTI) is a common and distressing condition disproportionately affecting females. It also accounts for a substantial proportion of antibiotic prescribing in primary care. Repeated antibiotic exposure contributes to adverse effects, disruption of the urogenital microbiome and the accelerating global threat of antimicrobial resistance. Consequently, contemporary clinical guidelines increasingly emphasise non-antibiotic prophylactic strategies as a core component of rUTI management. This narrative review synthesises contemporary evidence and guideline recommendations from the European Association of Urology (EAU), the National Institute for Health and Care Excellence (NICE), and the American Urological Association (AUA) on non-antibiotic prophylaxis for rUTI. It places particular focus on practical implementation in primary care. Behavioural and risk-factor optimisation, methenamine hippurate, topical estrogen, D-mannose, probiotics, cranberry products, immunoactive prophylaxis and intravesical therapies are reviewed. These are appraised with respect to efficacy, safety, tolerability, accessibility and quality of evidence. This review highlights key differences in guideline positioning and identifies areas of ongoing uncertainty and future research. Additionally, this review explores the central role of general practitioners in confirming diagnosis and initiating first-line non-antibiotic prophylaxis. Moreover, their role in supporting shared decision-making and managing timely specialist referral, where appropriate, is highlighted. Considerations for both men and women with rUTI are discussed. To support the translation of evidence into practice, this article includes pragmatic clinical tools, such as a shared decision-making aid, a stepwise treatment algorithm, and a structured risk-factor checklist. By integrating evidence-based non-antibiotic strategies into routine care, clinicians can reduce antibiotic exposure, improve patient outcomes, and respond proactively to the global challenge of antimicrobial resistance.<\/jats:p>","DOI":"10.31083\/bjhm49956","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:55:28Z","timestamp":1783421728000},"source":"Crossref","is-referenced-by-count":0,"title":["Non-Antibiotic Prophylaxis for Recurrent Urinary Tract Infection: A Narrative Review &amp; Clinical Guide for Primary and Hospital Care"],"prefix":"10.31083","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-8634","authenticated-orcid":true,"given":"Vaki","family":"Antoniou","sequence":"first","affiliation":[{"name":"Department of Urology, Barking Havering and Redbridge NHS Trust, RM7 0AG Essex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-6478","authenticated-orcid":true,"given":"Bhaskar","family":"Somani","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Southampton NHS Trust, SO16 6YD Hampshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Akkerman AE, Kuyvenhoven MM, Verheij TJM, van Dijk L. Antibiotics in Dutch general practice: nationwide electronic GP database and national reimbursement rates. Pharmacoepidemiology and Drug Safety. 2008; 17: 378\u2013383.","DOI":"10.1002\/pds.1501"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"van Driel AA, Notermans DW, Meima A, Mulder M, Donker GA, Stobberingh EE, et al. Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period. European Journal of Clinical Microbiology & Infectious Diseases. 2019; 38: 2151\u20132158.","DOI":"10.1007\/s10096-019-03655-3"},{"key":"ref3","unstructured":"National Institute for Health and Care Excellence. Urinary tract infection (recurrent): antimicrobial prescribing. 2024. Available at: https:\/\/www.nice.org.uk\/guidance\/ng112 (Accessed: 10 April 2026)."},{"key":"ref4","unstructured":"Bonkat G, Kranz J, Cai T, Geerlings SE, K\u00f6ves B, Schubert S, et al. EAU Guidelines on Urological Infections. EAU Guidelines Office: Arnhem, the Netherlands. 2026."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ackerman AL, Bradley M, D\u2019Anci KE, Hickling D, Kim SK, Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA\/CUA\/SUFU Guideline (2025). The Journal of Urology. 2026; 215: 3\u201312.","DOI":"10.1097\/JU.0000000000004723"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Simenacz A, Antoniou V, Somani BK. Review of non-antibiotic treatment and prevention of recurrent UTIs - a summary of current guidance and suggested treatment algorithm. Therapeutic Advances in Infectious Disease. 2025; 12: 20499361251395915.","DOI":"10.1177\/20499361251395915"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Advani SD, Thaden JT, Perez R, Stair SL, Lee UJ, Siddiqui NY. State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women. Clinical Infectious Diseases. 2025; 80: e31\u2013e42.","DOI":"10.1093\/cid\/ciae653"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Molina JJ, Flores-Mireles AL. CAUTIon - not all UTIs are the same. Nature Reviews. Urology. 2025; 22: 799\u2013814.","DOI":"10.1038\/s41585-025-01065-z"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Cox S, Vleeming M, Giorgi W, Dinant GJ, Cals J, de Bont E. Patients\u2019 Experiences, Expectations, Motivations, and Perspectives around Urinary Tract Infection Care in General Practice: A Qualitative Interview Study. Antibiotics. 2023; 12: 241.","DOI":"10.3390\/antibiotics12020241"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Assmus MA, McLarty R, Senthilselvan A, De SK. Direct to cystoscopy: A prospective quality assessment of patient preferences. Canadian Urological Association Journal. 2020; 14: 118\u2013121.","DOI":"10.5489\/cuaj.6013"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Becher E, Tong A, Taneja SS. Urologic Imaging. In Chapple C, Steers W, Evans C (eds.) Urologic Principles and Practice (pp. 201\u2013256). Springer: Cham. 2020.","DOI":"10.1007\/978-3-030-28599-9_13"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Bright E, Cotterill N, Drake M, Abrams P. Developing and validating the International Consultation on Incontinence Questionnaire bladder diary. European Urology. 2014; 66: 294\u2013300.","DOI":"10.1016\/j.eururo.2014.02.057"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Internal Medicine. 2018; 178: 1509\u20131515.","DOI":"10.1001\/jamainternmed.2018.4204"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Hakam N, Guzman Fuentes JL, Nabavizadeh B, Sudhakar A, Li KD, Nicholas C, et al. Outcomes in Randomized Clinical Trials Testing Changes in Daily Water Intake: A Systematic Review. JAMA Network Open. 2024; 7: e2447621.","DOI":"10.1001\/jamanetworkopen.2024.47621"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Fihn SD, Boyko EJ, Chen CL, Normand EH, Yarbro P, Scholes D. Use of spermicide-coated condoms and other risk factors for urinary tract infection caused by Staphylococcus saprophyticus. Archives of Internal Medicine. 1998; 158: 281\u2013287.","DOI":"10.1001\/archinte.158.3.281"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Harding C, Chadwick T, Homer T, Lecouturier J, Mossop H, Carnell S, et al. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technology Assessment. 2022; 26: 1\u2013172.","DOI":"10.3310\/QOIZ6538"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"King W, Homer T, Harding C, Mossop H, Chadwick T, Abouhajar A, et al. Cost-effectiveness of methenamine hippurate compared with antibiotic prophylaxis for the management of recurrent urinary tract infections in secondary care: a multicentre, open-label, randomised, non-inferiority trial. BMJ Open. 2024; 14: e074445.","DOI":"10.1136\/bmjopen-2023-074445"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Li JM, Cosler LE, Harausz EP, Myers CE, Kufel WD. Methenamine for urinary tract infection prophylaxis: A systematic review. Pharmacotherapy. 2024; 44: 197\u2013206.","DOI":"10.1002\/phar.2895"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Hobaica NC, De Oliveira GC, Porto BC, Passerotti CC, Da Silva Sardenberg RA, Otoch JP, et al. Effectiveness of methenamine hippurate in preventing urinary tract infections: an updated systematic review, meta-analysis and trial sequential analysis of randomized controlled trials. BMC Urology. 2025; 25: 30.","DOI":"10.1186\/s12894-025-01708-8"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Bakhit M, Krzyzaniak N, Hilder J, Clark J, Scott AM, Mar CD. Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. The British Journal of General Practice. 2021; 71: e528\u2013e537.","DOI":"10.3399\/BJGP.2020.0833"},{"key":"ref21","unstructured":"SmPC. Methenamine hippurate 1 g tablets. 2024. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/12707\/smpc#gref (Accessed: 23 December 2025)."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Chen YY, Su TH, Lau HH. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. International Urogynecology Journal. 2021; 32: 17\u201325.","DOI":"10.1007\/s00192-020-04397-z"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Tan-Kim J, Shah NM, Do D, Menefee SA. Efficacy of vaginal estrogen for recurrent urinary tract infection prevention in hypoestrogenic women. American Journal of Obstetrics and Gynecology. 2023; 229: 143.e1\u2013143.e9.","DOI":"10.1016\/j.ajog.2023.05.002"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Antoniou V, Somani BK. Topical and Oral Oestrogen for Recurrent Urinary Tract Infection-Evidence-based Review of Literature, Treatment Recommendations, and Correlation with the European Association of Urology Guidelines on Urological Infections. European Urology Focus. 2022; 8: 1768\u20131774.","DOI":"10.1016\/j.euf.2022.05.006"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Minkin MJ, Maamari R, Reiter S. Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. International Journal of Women\u2019s Health. 2013; 5: 133\u2013139.","DOI":"10.2147\/IJWH.S41897"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Scaglione F, Musazzi UM, Minghetti P. Considerations on D-mannose Mechanism of Action and Consequent Classification of Marketed Healthcare Products. Frontiers in Pharmacology. 2021; 12: 636377.","DOI":"10.3389\/fphar.2021.636377"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Hayward G, Mort S, Hay AD, Moore M, Thomas NPB, Cook J, et al. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial. JAMA Internal Medicine. 2024; 184: 619\u2013628.","DOI":"10.1001\/jamainternmed.2024.0264"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Kranj\u010dec B, Pape\u0161 D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World Journal of Urology. 2014; 32: 79\u201384.","DOI":"10.1007\/s00345-013-1091-6"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Lenger SM, Chu CM, Ghetti C, Durkin MJ, Jennings Z, Wan F, et al. d-Mannose for Recurrent Urinary Tract Infection Prevention in Postmenopausal Women Using Vaginal Estrogen: A Randomized Controlled Trial. Urogynecology. 2023; 29: 367\u2013377.","DOI":"10.1097\/SPV.0000000000001270"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Murali Krishna M, Joseph M, Pereira V, Nizami A, Ezenna C, Sadasivan Sreemathy L. D-Mannose for prevention of recurrent urinary tract infection in adult women: An updated systematic review and meta-analysis of randomized controlled trials. Journal of Infection Prevention. 2025; 26: 258\u2013267.","DOI":"10.1177\/17571774251394869"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Vargas CEF, Mutarelli A, Menegardo LG, Silva AKBD, Vieira PRB, Luz JD, et al. Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials. Jornal Brasileiro De Nefrologia. 2025; 47: e20250169.","DOI":"10.1590\/2175-8239-JBN-2025-0169en"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Cooper TE, Teng C, Howell M, Teixeira-Pinto A, Jaure A, Wong G. D-mannose for preventing and treating urinary tract infections. The Cochrane Database of Systematic Reviews. 2022; 8: CD013608.","DOI":"10.1002\/14651858.CD013608.pub2"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunology and Medical Microbiology. 2003; 35: 131\u2013134.","DOI":"10.1016\/S0928-8244(02)00465-0"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clinical Infectious Diseases. 2011; 52: 1212\u20131217.","DOI":"10.1093\/cid\/cir183"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Gupta V, Mastromarino P, Garg R. Effectiveness of Prophylactic Oral and\/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases. 2024; 78: 1154\u20131161.","DOI":"10.1093\/cid\/ciad766"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Mishra A, Jena SK, Srinivasan A, Tripathy A, Maiti R, Hota D. Effect of an Add-On Multi-Strain Probiotic Formulation in the Prevention of Recurrent Urinary Tract Infections: A Double-Blind Randomized Placebo-Controlled Trial. Microbiology Research. 2024; 15: 2330\u20132340.","DOI":"10.3390\/MICROBIOLRES15040156"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"New FJ, Theivendrampillai S, Julieb\u00f8-Jones P, Somani B. Role of Probiotics for Recurrent UTIs in the Twenty-First Century: a Systematic Review of Literature. Current Urology Reports. 2022; 23: 19\u201328.","DOI":"10.1007\/s11934-022-01085-x"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Emami E, Mt Sherwin C, Heidari-Soureshjani S. Effect of Probiotics on Urinary Tract Infections in Children: A Systematic Review and Meta-Analysis. Current Reviews in Clinical and Experimental Pharmacology. 2023; 19: 111\u2013121.","DOI":"10.2174\/2772432817666220501114505"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. The Cochrane Database of Systematic Reviews. 2023; 4: CD001321.","DOI":"10.1002\/14651858.CD001321.pub6"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Gkiourtzis N, Stoimeni A, Glava A, Chantavaridou S, Michou P, Cheirakis K, et al. Prophylaxis Options in Children With a History of Recurrent Urinary Tract Infections: A Systematic Review. Pediatrics. 2024; 154: e2024066758.","DOI":"10.1542\/peds.2024-066758"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Hakim RA, Putri DE, Rahajeng. Cranberry extract for urinary tract infection treatment in pregnancy: A systematic review. Majalah Obstetri & Ginekologi. 2025; 33.","DOI":"10.20473\/mog.v33i22025.121-131"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Tsiakoulias E, Gravas S, Hadjichristodoulou C, Oikonomou KG, Kyritsi M, Dadouli K, et al. Randomized, placebo-controlled, double-blinded study of prophylactic cranberries use in women with recurrent uncomplicated cystitis. World Journal of Urology. 2024; 42: 27.","DOI":"10.1007\/s00345-023-04741-0"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Xiong Z, Gao Y, Yuan C, Jian Z, Wei X. Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review. Frontiers in Nutrition. 2024; 11: 1422121.","DOI":"10.3389\/fnut.2024.1422121"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Moro C, Phelps C, Veer V, Jones M, Glasziou P, Clark J, et al. Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis. European Urology Focus. 2024; 10: 947\u2013957.","DOI":"10.1016\/j.euf.2024.07.002"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Paeng CH, Sprague M, Jackevicius CA. Interaction between warfarin and cranberry juice. Clinical Therapeutics. 2007; 29: 1730\u20131735.","DOI":"10.1016\/j.clinthera.2007.08.018"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Li Z, Seeram NP, Carpenter CL, Thames G, Minutti C, Bowerman S. Cranberry does not affect prothrombin time in male subjects on warfarin. Journal of the American Dietetic Association. 2006; 106: 2057\u20132061.","DOI":"10.1016\/j.jada.2006.09.012"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Madden E, McLachlan C, Oketch-Rabah H, Calder\u00f3n AI. Safety of Cranberry: Evaluation of Evidence of Kidney Stone Formation and Botanical Drug-Interactions. Planta Medica. 2021; 87: 803\u2013817.","DOI":"10.1055\/a-1497-6241"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology. 2001; 57: 26\u201329.","DOI":"10.1016\/s0090-4295(00)00884-0"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology. 2005; 174: 590\u2013594; quiz 801.","DOI":"10.1097\/01.ju.0000165168.68054.f8"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Mak Q, Greig J, Dasgupta P, Malde S, Raison N. Bacterial Vaccines for the Management of Recurrent Urinary Tract Infections: A Systematic Review and Meta-analysis. European Urology Focus. 2024; 10: 761\u2013769.","DOI":"10.1016\/j.euf.2024.04.002"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Volont\u00e8 S, De Vicari D, Cola A, Barba M, Frigerio M. Efficacy and Safety of Uro-Vaxom in Urinary Tract Infection Prevention: A Systematic Literature Review. Journal of Clinical Medicine. 2025; 14: 3836.","DOI":"10.3390\/jcm14113836"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Magasi P, P\u00e1novics J, Ill\u00e9s A, Nagy M. Uro-Vaxom\u2227\u00ae and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. European Urology. 1994; 26: 137\u2013140.","DOI":"10.1159\/000475363"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Brodie A, El-Taji O, Jour I, Foley C, Hanbury D. A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89\u00ae) for Prophylaxis of Recurrent Urinary Tract Infections. Current Urology. 2020; 14: 130\u2013134.","DOI":"10.1159\/000499248"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Nestler S, Gr\u00fcne B, Schilchegger L, Suna A, Perez A, Neisius A. Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: a comparative single-centre study. International Urology and Nephrology. 2021; 53: 2267\u20132272.","DOI":"10.1007\/s11255-021-02987-4"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Ram\u00edrez-Sevilla C, G\u00f3mez-Lanza E, Llopis-Manzanera J, Cetina-Herrando A, Puyol-Pall\u00e0s JM. Effectiveness and health cost analysis between immunoprophylaxis with MV140 autovaccine, MV140 vaccine and continuous treatment with antibiotics to prevent recurrent urinary tract infections. Actas Urologicas Espanolas. 2023; 47: 27\u201333.","DOI":"10.1016\/j.acuroe.2022.08.016"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Lopes FA, Miranda M, Ye A, Rodrigues J, P\u00e9-Leve P, Palma Reis J, et al. Immunoprophylaxis with MV140 Is Effective in the Reduction of Urinary Tract Infections-A Prospective Real-Life Study. Vaccines. 2024; 12: 1426.","DOI":"10.3390\/vaccines12121426"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Ram\u00edrez Sevilla C, G\u00f3mez Lanza E, Puyol Pall\u00e0s M. Immunoactive Prophylaxis Protocol of Uncomplicated Recurrent Urinary Tract Infections in a Cohort of 1104 Women Treated with Uromune\u00ae Vaccine. Life. 2024; 14: 464.","DOI":"10.3390\/life14040464"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Stangl FP, Schneidewind L, Kiss B, Kranz J, Wagenlehner FM, Johansen TEB, et al. Non-Antibiotic Prophylaxis for Recurrent UTIs in Neurogenic Lower Urinary Tract Dysfunction (NAPRUN): Study Protocol for a Prospective, Longitudinal Multi-Arm Observational Study. Methods and Protocols. 2023; 6: 52.","DOI":"10.3390\/mps6030052"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Fr\u00f6lich R, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. The Lancet. Infectious Diseases. 2017; 17: 528\u2013537.","DOI":"10.1016\/S1473-3099(17)30108-1"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Ochoa DC, Healy R. Intravesical Agents for Prevention of Recurrent Urinary Tract Infections. European Urology Focus. 2024; 10: 726\u2013730.","DOI":"10.1016\/j.euf.2024.08.001"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Contreras-Garc\u00eda R, Garc\u00eda-Perdomo HA. Effectiveness of intravesical glycosaminoglycans in the treatment of recurrent urinary tract infections: Systematic review and meta-analysis. Journal of Clinical Urology. 2025; 18: 186\u2013194.","DOI":"10.1177\/20514158231198553"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Corona G, Capogrosso P, Baldini S, Rastrelli G, Vignozzi L, Romero-Otero J, et al. Hyaluronic acid and chondroitin sulphate instillation in chronic bladder diseases: a meta-analysis. BJU International. 2026; 137: 36\u201348.","DOI":"10.1111\/bju.70016"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Ciani O, Arendsen E, Romancik M, Lunik R, Costantini E, Di Biase M, et al. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. BMJ Open. 2016; 6: e009669.","DOI":"10.1136\/bmjopen-2015-009669"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Damiano R, Quarto G, Bava I, Ucciero G, De Domenico R, Palumbo MI, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. European Urology. 2011; 59: 645\u2013651.","DOI":"10.1016\/j.eururo.2010.12.039"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Madurga Patuel B, Gonz\u00e1lez-L\u00f3pez R, Resel Folkersma L, Machado Fern\u00e1ndez G, Adot Zurbano JM, Bonillo M\u00c1, et al. Recommendations on the use of intravesical hyaluronic acid instillations in bladder pain syndrome. Actas Urologicas Espanolas. 2022; 46: 131\u2013137.","DOI":"10.1016\/j.acuroe.2022.02.007"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment. The Journal of Urology. 2015; 193: 1545\u20131553.","DOI":"10.1016\/j.juro.2015.01.086"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Pietropaolo A, Jones P, Moors M, Birch B, Somani BK. Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): a Systematic Review. Current Urology Reports. 2018; 19: 78.","DOI":"10.1007\/s11934-018-0834-8"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Kulkarni PA, Cort\u00e9s-Penfield NW, Brehm TJ, Wagenlehner F, Gupta K, Leitner L, et al. State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis. Clinical Infectious Diseases. 2026; 82: 1\u201313.","DOI":"10.1093\/cid\/ciaf483"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Borgert BJ, Wallen EM, Pham MN. Prostatitis: A Review. JAMA. 2025; 334: 1003\u20131013.","DOI":"10.1001\/jama.2025.11499"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Riemma G, Vinci D, La Verde M, Caniglia FM, Scalzone G, Torella M. Adding collagen, propolis plus quercetin, bacillus coagulans, hyaluronic acid and chondroitin sulphate to D-mannose avoids symptoms and prevents recurrence in women with recurrent urinary tract infections: a single-blind randomized controlled trial. Expert Review of Anti-Infective Therapy. 2025; 23: 523\u2013530.","DOI":"10.1080\/14787210.2025.2487162"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/6\/10.31083\/BJHM49956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:59:42Z","timestamp":1783421982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/6\/10.31083\/BJHM49956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1750-8460(26)02994-0"],"URL":"https:\/\/doi.org\/10.31083\/bjhm49956","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"49956"}}